Long non-coding RNA NHEG1/hsa-miR-665/HMGB1 axis is involved in the regulation of neuroblastoma progression.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101581063 Publication Model: Print Cited Medium: Internet ISSN: 2165-5987 (Electronic) Linking ISSN: 21655979 NLM ISO Abbreviation: Bioengineered Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Philadelphia, PA : Taylor & Francis
      Original Publication: Austin : Landes Bioscience
    • Subject Terms:
      Disease Progression* ; Gene Expression Regulation, Neoplastic*; HMGB1 Protein/*metabolism ; MicroRNAs/*metabolism ; Neuroblastoma/*genetics ; Neuroblastoma/*pathology ; RNA, Long Noncoding/*metabolism; Base Sequence ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/genetics ; Child, Preschool ; Female ; Gene Silencing ; Humans ; Infant ; Male ; MicroRNAs/genetics ; Neoplasm Invasiveness ; Phenotype ; RNA, Long Noncoding/genetics ; Up-Regulation/genetics
    • Abstract:
      Long non-coding (lncRNA) neuroblastoma highly expressed 1 (NHEG1) has been reorganized as a prognostic factor in neuroblastoma (NB), but the molecular mechanisms in the suppression of neuroblastoma remain to be elucidated. In our study, we explored the functional roles of lncRNA NHEG1 in neuroblastoma and the underlying molecular mechanism. We collected NB tumor samples and adjacent normal tissues to compare lncRNA NHEG1 expression. Through bioinformatic target prediction, we selected potential downstream effectors of lncRNA NHEG1 for functional validation in NB cell lines. We observed that lncRNA NHEG1 was significantly upregulated in NB tissues as compared to the normal tissues. In NB tissues, lncRNA NHEG1 expression showed an inverse correlation with hsa-miR-665 (miR-655), but a positive correlation with high mobility group box 1 (HMGB1). In NB cell lines, lncRNA NHEG1 knockdown caused the upregulation of miR-665 and the downregulation of HMGB1. Through a series of functional assays, we further demonstrated that lncRNA Nheg1 knockdown suppressed cell proliferation, migration and invasion of NB cells, which could be rescued by miR-665 inhibitor and HMGB1 overexpression. Together, our data demonstrated that lncRNA NHEG1 serves as a competitive partner to negatively regulate the activity of miR-665, which relieves the inhibition on HMGB1 expression and promotes the aggressive phenotype of neuroblastoma cells. Our study indicates that lncRNA NHEG1/miR-665/HMGB1 axis may play an important role in regulating the aggressiveness and the progression of neuroblastoma.
    • References:
      Mol Oncol. 2020 Jan;14(1):180-196. (PMID: 31637848)
      Theranostics. 2019 Jan 30;9(4):986-1000. (PMID: 30867811)
      Oncol Lett. 2018 Nov;16(5):5697-5708. (PMID: 30344725)
      Mol Ther. 2020 Mar 4;28(3):946-962. (PMID: 31982037)
      Oncol Rep. 2021 Jan;45(1):202-216. (PMID: 33416133)
      Nat Rev Drug Discov. 2013 Nov;12(11):847-65. (PMID: 24172333)
      Theranostics. 2017 Sep 21;7(17):4099-4117. (PMID: 29158813)
      Nucleic Acids Res. 2016 Jan 4;44(D1):D231-8. (PMID: 26612864)
      Onco Targets Ther. 2017 Sep 11;10:4465-4474. (PMID: 28979138)
      Cancer Lett. 2002 Oct 28;184(2):127-47. (PMID: 12127685)
      Oncol Rep. 2021 Feb;45(2):469-480. (PMID: 33416160)
      Nat Rev Clin Oncol. 2014 Mar;11(3):145-56. (PMID: 24492836)
      Neuroreport. 2020 Dec 9;31(17):1189-1198. (PMID: 33044324)
      Nature. 2000 Feb 24;403(6772):901-6. (PMID: 10706289)
      Cancer Manag Res. 2019 Apr 11;11:3111-3123. (PMID: 31114354)
      Mol Med Rep. 2018 Sep;18(3):2661-2668. (PMID: 30015865)
      Cancer Res. 2014 Jul 15;74(14):3753-63. (PMID: 25028366)
      Cancer Cell Int. 2021 Jan 9;21(1):36. (PMID: 33422081)
      Cancer Manag Res. 2020 Dec 30;12:13451-13459. (PMID: 33408517)
      Int J Mol Sci. 2016 Dec 09;17(12):. (PMID: 27941681)
      Front Cell Dev Biol. 2020 Nov 20;8:559553. (PMID: 33330445)
      Int J Oncol. 2009 Apr;34(4):931-8. (PMID: 19287950)
      Oncotarget. 2018 Sep 4;9(69):33186-33201. (PMID: 30237861)
      Oncol Lett. 2016 Sep;12(3):2133-2138. (PMID: 27602152)
      PLoS One. 2013 Sep 10;8(9):e73803. (PMID: 24040078)
      Oncotarget. 2017 Sep 14;8(46):80666-80678. (PMID: 29113334)
      Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. (PMID: 12434020)
      Neurosci Lett. 2021 Jan 1;740:135482. (PMID: 33161106)
      Biochem Biophys Res Commun. 2020 May 28;526(2):396-403. (PMID: 32223925)
      Life Sci. 2018 Jun 1;202:1-10. (PMID: 29551576)
      Theranostics. 2020 Jan 1;10(4):1555-1571. (PMID: 32042322)
      PLoS One. 2020 Feb 10;15(2):e0227928. (PMID: 32040529)
      Neuroreport. 2011 Sep 14;22(13):652-4. (PMID: 21841455)
      N Engl J Med. 2010 Jun 10;362(23):2202-11. (PMID: 20558371)
      Food Chem Toxicol. 2019 Feb;124:336-348. (PMID: 30578841)
    • Contributed Indexing:
      Keywords: HMGB1; Lncrna NHEG1; miR-665; neuroblastoma
    • Accession Number:
      0 (HMGB1 Protein)
      0 (HMGB1 protein, human)
      0 (MIRN665 microRNA, human)
      0 (MicroRNAs)
      0 (RNA, Long Noncoding)
    • Publication Date:
      Date Created: 20211210 Date Completed: 20220217 Latest Revision: 20220217
    • Publication Date:
      20221213
    • Accession Number:
      PMC8810076
    • Accession Number:
      10.1080/21655979.2021.1983277
    • Accession Number:
      34889712